These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 27987984)

  • 1. Biological and structural analyses of bovine heparin fractions of intermediate and high molecular weight.
    Nogueira AV; Drehmer DL; Iacomini M; Sassaki GL; Cipriani TR
    Carbohydr Polym; 2017 Feb; 157():72-78. PubMed ID: 27987984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
    Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin from bovine intestinal mucosa: glycans with multiple sulfation patterns and anticoagulant effects.
    Tovar AM; Capillé NV; Santos GR; Vairo BC; Oliveira SN; Fonseca RJ; Mourão PA
    Thromb Haemost; 2012 May; 107(5):903-15. PubMed ID: 22437650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fractionation and structural features of two heparin families with high antithrombotic, antilipemic and anticoagulant activities.
    Bianchini P; Osima B; Parma B; Nader HB; Dietrich CP; Casu B; Torri G
    Arzneimittelforschung; 1985; 35(8):1215-9. PubMed ID: 4074437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protamine neutralisation of low molecular weight heparins and their oligosaccharide components.
    Schroeder M; Hogwood J; Gray E; Mulloy B; Hackett AM; Johansen KB
    Anal Bioanal Chem; 2011 Jan; 399(2):763-71. PubMed ID: 20922518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
    Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
    Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Converting the Distinct Heparins Sourced from Bovine or Porcine Mucosa into a Single Anticoagulant Drug.
    Tovar AMF; Vairo BC; Oliveira SMCG; Glauser BF; Santos GRC; Capillé NV; Piquet AA; Santana PS; Micheli KVA; Pereira MS; Vilanova E; Mourão PAS
    Thromb Haemost; 2019 Apr; 119(4):618-632. PubMed ID: 30791055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin and low molecular weight heparin in thrombosis and beyond.
    Mousa SA
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PiCT
    Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and activity of a new low-molecular-weight heparin produced by enzymatic ultrafiltration.
    Fu L; Zhang F; Li G; Onishi A; Bhaskar U; Sun P; Linhardt RJ
    J Pharm Sci; 2014 May; 103(5):1375-83. PubMed ID: 24634007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrasonic-assisted preparation of a low molecular weight heparin (LMWH) with anticoagulant activity.
    Achour O; Bridiau N; Godhbani A; Le Joubioux F; Bordenave Juchereau S; Sannier F; Piot JM; Fruitier Arnaudin I; Maugard T
    Carbohydr Polym; 2013 Sep; 97(2):684-9. PubMed ID: 23911501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.
    Kuziej J; Litinas E; Hoppensteadt DA; Liu D; Walenga JM; Fareed J; Jeske W
    Clin Appl Thromb Hemost; 2010 Aug; 16(4):377-86. PubMed ID: 20460347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments.
    Fareed J; Walenga JM; Williamson K; Emanuele RM; Kumar A; Hoppensteadt DA
    Semin Thromb Hemost; 1985 Jan; 11(1):56-74. PubMed ID: 3883500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralisation of the anti-coagulant effects of heparin by histones in blood plasma and purified systems.
    Longstaff C; Hogwood J; Gray E; Komorowicz E; Varjú I; Varga Z; Kolev K
    Thromb Haemost; 2016 Mar; 115(3):591-9. PubMed ID: 26632486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From unfractionated heparins to low molecular weight heparins.
    Hirsh J
    Acta Chir Scand Suppl; 1990; 556():42-50. PubMed ID: 1705072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic monitoring of unfractionated heparin - trials and tribulations.
    Baluwala I; Favaloro EJ; Pasalic L
    Expert Rev Hematol; 2017 Jul; 10(7):595-605. PubMed ID: 28632418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.